Therapeutic Insights against Oxidative Stress Induced Diabetic Nephropathy: A Review

Namrata Agarwal, Pritam Sadhukhan, Sukanya Saha and Parames C Sil

Division of Molecular Medicine, Bose Institute, P-1/12, CIT Scheme VII M, Kolkata-700054, India

Corresponding author:
Parames C Sil

parames@jcbose.ac.in
Division of Molecular Medicine, Bose Institute, P-1/12, CIT Scheme VII M, Kolkata-700054, West Bengal, India.
Tel: 9133-25693243

Citation: Sil PC. Therapeutic Insights against Oxidative Stress Induced Diabetic Nephropathy: A Review . J Autoimmun Disod. 2015, 1:1.

Abstract

Diabetes mellitus (DM) is an outcome of an absolute or relative deficiency of insulin which may be due to autoimmune destruction. It is mainly characterised by hyperglycemia, causes auto-oxidation of glucose, glycation of proteins and activation of polyol mechanism. This leads to oxidative stress, defined as an increase in the intracellular level of reactive oxygen species (ROS). Overproduction of ROS contributes to several microvascular and macrovascular complications of DM including diabetic nephropathy (DN). DN is a primary cause of chronic kidney disease and end-stage renal failure in various parts of the world. Minimizing the risk factors associated with DN is insufficient in lowering the vulnerability of this disorder. Henceforth, an increased knowledge on the role of oxidative stress would lead the way to the exploration of a number of molecules having antioxidant property as therapeutic option. These agents could reduce the severity of DN by decreasing the level of ROS and modulating an array of signalling cascade, thereby ameliorating oxidative stress via its antioxidative and immunomodulatory properties. This review provides valuable information concerning the recent advancements in understanding the role of well-known therapeutic agents in alleviating oxidative stress induced renovascular complications in DM. This review also encompasses the role of different natural products on their effect on the T-cell driven immune response in autoimmune diabetic nephropathy.

Keywords: Diabetic nephropathy; Oxidative stress; ROS; Antioxidant molecules

Introduction

With the unhealthy nutritional transition and changes in human behavior and lifestyle, the incidence of diabetes mellitus (DM) in the society is rising out of the blue. DM, a common endocrine metabolic disorder, characterized by a state of chronic hyperglycemia, is a major concern as it is a universal cause of morbidity and mortality [1-3]. Globally, the number of diabetic patients is on alarming rise which will be heading to around 592 million by 2035 from the present scenario of 382 million affected people as estimated by International Diabetes Federation (IDF). Although it is a universal public health threat, present trend indicates that the Asian countries contribute to 60% of world’s diabetic population due to the rapid occurrence of socio-economic growth and industrialization in many of these countries [4]. The countries which are at greater risk in Asia include India, China and Japan [5]. Despite of the high mortality rate of diabetes patients, the more serious part is the painstaking morbidity associated with it [6]. The debilitating symptoms of DM include weight loss, polyuria, polydipsia and polyphagia [7]. Irrespective of such varied symptoms, onset of this disease is due to the body’s inability to control blood glucose level. This is mainly because of the (i) failure of glucose access into the cells; (ii) reduction in the utilization of glucose by different tissues; and (iii) up turn of glucose synthesis by liver [8].

Universally, DM is classified into three different forms: type 1 DM (T1DM), type 2 DM (T2DM) and Gestational DM. Type 1 DM or insulin dependent diabetes mellitus (IDDM) occurs due to insulin deficiency as an after effect of autoimmune destruction of pancreatic β-cells; Type 2 DM, also called non-insulin dependent diabetes mellitus (NIDDM), occurs as a result of insensitivity of
cells to insulin and therefore subsequent loss of β-cell function [9]; and gestational diabetes mellitus, which develops during pregnancy, due to hormonal changes that alter the body’s ability to make use of insulin leading to carbohydrate intolerance and usually vanishes after the birth of the child. It does not confirm the birth of a diabetic child [10-12]. It is well accepted that autoimmunity is a major factor in T1DM. In the pathogenesis and progression of several microvascular and macrovascular complications including diabetic nephropathy, a number of inflammatory and angiogenic molecules are important modulators in different pathways of these pathophysiological conditions. Like T1DM, T2DM is also being recognized for having autoimmune aspects because of the circulating autoantibodies against β cells and self-reactive T cells. Literature also suggests the presence of these β-cell autoantibodies in initially non-insulin dependent diabetic children with the clinical features of T2DM [13].

The major complications of DM include various macrovascular diseases like cardiovascular disease, stroke and peripheral vascular disease, all resulting from complications related to damaged blood vessels [14]. Whereas, the key microvascular complications involve damage to the eyes (diabetic retinopathy), kidneys (diabetic nephropathy) and nerves (diabetic neuropathy) [15-17] (Figure 1). Among the various complications of DM, approximately 40% of patients are affected by diabetic nephropathy (DN) [18]. DN is a major cause of death from diabetes [19] and also a leading cause of end stage renal disease in many developing countries [20]. Symptoms which are usually absent at an early stage develops with time [21] and are characterized by the development of proteinuria and decrease in glomerular filtration rate (GFR) [22]. Patients suffering from such end stage complications require medical attentions like dialysis or even kidney transplant. Involvement of immune system and inflammatory processes in the development and progression of DN has been recently reported [23,24]. The activation of T cells in type 1 diabetes is also found to be associated with DN. Influx of T cells associates with albumin excretion rate and glomerular filtration surface. A number of cytokines like IL-18 and TNF-α have also been found to lead the way to DN [25,26]. Collectively immune system seems to be involved in causing structural and functional changes to kidney leading to DN. Also multiple publications suggest that free radicals originating from oxidative stress and failure of the intrinsic antioxidants during diabetes are the main culprits having a significant contribution in the development and progression of life threatening DN [27-29]. Apart from this, some other risk factors like increased blood pressure and genetic alterations also play a causal role in DN [30].

Oxidative stress is an imbalance between oxidant level i.e., pro-oxidants and antioxidants within the body. It results when harmful free radicals are generated in excess and body’s natural antioxidants ability to detoxify them is perturbed [31]. This leads to inordinate formation and/or scanty removal of these free radicals which are mainly classified as Reactive oxygen species (ROS) and Reactive nitrogen species (RNS). ROS production occurs via divergent sources in a diabetic patient like enzymatic, non-enzymatic and mitochondrial pathways [32] and causes oxidation of various biomolecules including DNA, protein, carbohydrates...
and lipids [33]. Various cells like endothelial, vascular smooth muscle, tubular epithelial and mesangial cells start producing ROS under hyperglycemic condition thereby increasing the complications of diabetes, especially DN [34]. This ROS causes thickening of basement membrane within kidney glomerulus besides the progressive accumulation of extracellular matrix components in the mesangium [35].

Oxidative stress plays a causal role in several pathological conditions in the body and targeting them with antioxidants has shown to reduce the deleterious effects of ROS [36]. This makes different molecules having antioxidant activity, as the savior in such stressed situation. Such molecules have been found to counteract the harmful effect that occurs due to increased ROS in various disorders like heart disease, Alzheimer disease, aging and many others by removing free radical intermediates and inhibiting oxidation of other molecules [37-39]. High glucose level during diabetes leads to oxidative stress through different signaling pathways which produces detrimental situations like DN in our body [40,41]. Therefore, treating DN with innumerable antioxidant molecules that can exhibit effective results, has opened a newer therapeutic approach [35,42,43]. Use of product from plants has demonstrated their antioxidants effects [44-46]. Recently, the potential of drugs as antioxidants in treating DN has also been proven [47-49]. This review highlights the role of several recently studied antioxidant therapies, thereby combining the research reports of various studies, useful in preventing the pathogenesis of DN occurring due to oxidative stress.

**Oxidative stress and diabetic nephropathy**

Oxidative stress is a deleterious phenomenon within the body, mainly characterized by imbalance of cellular oxidation/reduction levels. It reduces the normal antioxidant defense system of the human body by decreasing the cellular antioxidant levels and lowering the activity and expression of antioxidant enzymes like superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), glutathione reductase (GR) etc. to scavenge free radicals [50-52]. The presence of high glucose level either due to resistance of cells to insulin or lack of insulin synthesis by pancreatic β cells leads to the condition commonly known as diabetes [3]. As discussed earlier, this condition plays an important role in the production of ROS by activating several cellular responses through different signaling pathways thereby leading to detrimental effects like DN. Quite a number of factors are involved in generation of oxidative stress during diabetes but the dominant role is played by increase in the production of several reactive radicals (peroxyl, hydroxyl and superoxide) and many other reactive compounds (hydrogen peroxide (H₂O₂), nitric oxide (NO), nitrogen dioxide (NO₂), nitrous oxide (HNO₂), hydrochlorous acid (HOCI) etc.) [53,54]. It is well established that
oxidative stress during DM ultimately leads to the knocking down of normal kidney homeostasis and proper functioning [21].

Evidence of increased ROS production in kidneys of both type 1 and type 2 DM affected patients via both enzymatic and non-enzymatic pathways have also been reported [55-57]. High glucose appears to act through the activation of protein kinase C (PKC) in diabetic glomeruli through de novo synthesis of diacylglycerol (DAG). This PKC produces ROS which in turn causes activation of PKC thereby causing increment of mesangial expansion, basement membrane thickening and dysfunction of endothelial cells leading to DN [15,58]. ROS formation also occurs due to the isoforms of nicotinamide adenine dinucleotide phosphate oxidases (NOXs), especially NOX-4, activated under hyperglycemic condition, which leads to endothelial dysfunction, inflammation and apoptosis [59,60]. Others like auto-oxidation of glucose, polyol pathway flux, increased formation of advanced glycation end (AGE) products and glycation of proteins under hyperglycemic conditions are also involved in causing direct and indirect renal damage by producing extensive amount of ROS [61,62].

Diabetes has also been found to be associated with an increment of renin-angiotensin system (RAS) activity including aldosterone production which plays an important and direct role in the production and activation of ROS leading to renal damage [63,64]. Elevated level of glucose leads to the activation of transforming growth factor-(TGF-β). Over expression of TGF-β or TGF-β type II receptor in the glomerular and tubulointerstitial compartments of the diabetic kidney has been reported in many studies. Enhanced level of TGF-β leads to renal hypertrophy, glomerulosclerosis and tubulointerstitial fibrosis in diabetic kidney [65,66]. Multiple literatures suggest that vascular endothelial growth factor (VEGF), a protein secreted by the podocytes and the mesangial cells of kidney, plays a role in the progression of DN [67,68]. Under oxidative stress condition, VEGF is increased and expressed by the kidney, plays a role in the progression of DN [67,68]. Under oxidative stress condition, VEGF is increased and expressed by the kidney, plays a role in the progression of DN [67,68]. Under oxidative stress condition, VEGF is increased and expressed by the kidney, plays a role in the progression of DN [67,68]. Under oxidative stress condition, VEGF is increased and expressed by the kidney, plays a role in the progression of DN [67,68]. Under oxidative stress condition, VEGF is increased and expressed by the kidney, plays a role in the progression of DN [67,68]. Under oxidative stress condition, VEGF is increased and expressed by the kidney, plays a role in the progression of DN [67,68].

Increased ROS production by different pathways leads to the activation of downstream molecules like p38 mitogen activated protein kinases (p38 MAPK), nuclear factor-κB (NF-κB) and TGF-β causing development of DN [35,42]. Growing evidence suggests that oxidative stress during hyperglycemic condition leads to the overproduction of superoxides (•O2−) by the uncoupling of eNOS [77]. This diminishes the level of an antioxidant enzyme SOD, the first metallo protein enzyme, which is involved in the conversion of super oxide anion radical (O2−) to H2O2 thereby removing the superoxide anions. Also the production of VEGF leads to the proteinuria thereby adding complications to DN [78,79]. On an overall perspective, it is found that under diabetic conditions, intracellular ROS is elevated due to many converging pathways and finally leads to nephropathic situation by activating an array of diverging signaling cascades (Figure 3).

Antioxidant therapies in amelioration of diabetic nephropathy

Antioxidants are the class of compounds which can potentially inhibit the oxidation of other intracellular molecules, protecting our body from the detrimental effects of free radicals [80]. Free radicals are the electron deficient, highly reactive molecules that can oxidize the cellular macromolecules causing severe damage to subcellular organelles [81,82]. It is necessary to timely scavenge these free radicals otherwise persistent exposure to them can lead to tissue degradation directing its way to a state of organ pathophysiology. To prevent the deleterious effects of free radicals, the effects of antioxidants are extensively studied [83-86]. Antioxidants act through different mechanisms at various sites exerting a number of biochemical effects. Researchers suggest that the hyperglycemia during DM often interfere with the intracellular ascorbate metabolism and results in the generation of free radicals thereby increasing the susceptibility of oxidative damage [87]. It has been experimentally shown in different diabetic models that the level of different antioxidants got decreased, both transcriptionally and post-transcriptionally, in kidney tissue [88,89]. It is also shown that prevention of the overproduction of ROS by the administration of exogenous antioxidants is an effective strategy in combating DN [35,90,91]. Numerous studies suggest that antioxidants improve the renal physiology in DN by acting directly against oxidative damage. Moreover, exogenous administration of antioxidants is capable of preventing the progression of DN. They can also effectively block the formation of excessive ROS and scavenge the preformed intracellular ROS. Some antioxidant molecules can even modulate the signaling cascade to resume the normal cellular homeostasis [15,21,42,92] (Figure 3).

Human body possesses natural antioxidants to control the level of ROS by scavenging them both enzymatically and non-enzymatically [93]. Enzymatic pathways include a platter of enzymes namely SOD, CAT, GPx, GR etc. Different nonenzymatic antioxidants include various vitamins (like vitamin A, C, E, carotenoids, α-lipoic acid, etc.), trace elements [like coenzyme Q10 (CoQ10), copper, selenium, zinc, etc.] and cofactors (like uric acid, folic acid, albumin, etc.). Antioxidant enzymes either readily converts the reactive free radical •O2− into H2O2 or activates intracellular pathways to regenerate other antioxidative metabolites [33]. These metabolites then react with the reactive radicals and change them into the stabilized form. Other than these metabolites or enzymes, certain genes (e.g., nuclear factor erythroid 2-related factor 2 (Nrf-2) and heme oxygenase-1 (HO-1)) and their end products are also capable in maintaining cellular homeostasis in oxidative stress related organ pathophysiological conditions including DN [94].

In addition to the ROS scavenging properties, exogenous antioxidant molecules are also capable of modulating different gene expression to improve the oxidative stress induced DN [95-
Antioxidants including various dietary phytochemicals have been shown to exhibit immunomodulatory effect by reducing destruction of pancreatic β-cells, enhancing immunotolerance and autoimmunity suppression [98]. Reports suggest that the inhibitors of NOXs are very helpful in reducing the level of blood glucose and urinary protein content [99,100]. Some antioxidants are also known to reduce the expression of VEGF and they can even diminish the 8-hydroxy-2′-deoxyguanosine (8-OHdG) and malondialdehyde (MDA) contents in urine [101]. They can improve the functionality of the glomerular and mesangial cells in kidney. Besides, different antioxidants can also regulate the glomerular expression of TGF-β1 and collagen IV proteins in the kidney under diabetic conditions [102,103]. Apart from these functions, antioxidants also inhibit high glucose induced activation of hexosamine, PKC, AGE pathways and NF-κB [62,104]. In addition, numerous reports have been published on antioxidants about their potential in down-regulating different pro-apoptotic genes and simultaneous up-regulation of different anti-apoptotic genes along with maintaining the normal mitochondrial homeostasis [105-107].

Antioxidants are pleiotropic biomolecules. Along with the control in the serum blood glucose level, some antioxidants are very effective in inhibiting some crucial signaling intermediates like angiotensin-2 converting enzyme (ACE), angiotensin-2 receptor blockers (ARB), and aldosterone blockers [108,109]. Selective antioxidants molecules can also activate eNOS, which in turn increases the bioavailability of nitric oxide and blocks the expression of angiotensin 2 and TGF-β thus inhibiting the progression of diabetes in kidney [93,110].

A number of antioxidants are known to ameliorate oxidative stress induced renovascular complications. The follow up study covers an area highlighting the recent literature on the detailing of the alleviating role of several antioxidants molecules against DN.

**Therapeutic plants**

A number of studies are going on to determine the importance of plants and their active ingredients all over the world [111,112]. Among these, several natural antioxidants have been reported to show beneficial consequences in putting a halt to the fatality of renal dysfunctions in DN. The active phytochemicals responsible for the activities of plant products have been identified in some and yet to be identified in others. Several molecules show their protective effects on kidney by lowering glucose level near to normal while some show direct effects on kidney [113,114]. Recent studies suggest that these compounds reduce the AGE levels, expression of TGF-β and other cytokines, etc. [115,116]. Moreover they also ameliorate the oxidative stress by modulating the functions of glomerular cells in the kidney. The therapeutic potential of different plants is under investigation to assess their anti-inflammatory and immunomodulatory activities. Many scientists are keenly engrossed to prevent and recover people from DN and a number of studies are going on for suitable inexpensive active principles capable of counteracting it with minimum side effects. Investigation of plant products for their pharmacological properties in the regulation of oxidative stress induced renovascular complications has become prime importance. An overview of some recent plants (their whole extracts or active compounds) playing a protective role in DN and their mechanistic implications are mentioned below.

**Terminalia arjuna**
Belonging to the family of Combretaceae, *Terminalia arjuna* (*T. arjuna*) has been well known among ayurvedic medicinal plants. The entire plant is full of many bioactive constituents like tannins, triterpenoid saponins, flavonoids, ellagic acid, gallic acid, oligomeric proanthocyanidins (OPCs), phytosterols etc. [117,118]. They are useful as therapeutic agents for the treatment of various physiological disorders [119]. A pentacyclic triterpenoid saponin, arjunolic acid (2,3,23-trihydroxyolean-12-en-28-oic acid; AA), isolated from the bark of this tree, is popularly known for its radical scavenging activity and potential antioxidant power [120] due to its hydrogen donation, metal ion chelating and the resonance stabilization of carboxyl radical property [120]. P. Manna et al. have portrayed the efficacy of AA in ameliorating STZ induced hyperglycemia and associated renal pathophysiology. This is due to the effect of AA in reducing oxidative as well as nitrosative stress and suppressing the activation of polyol pathway. Treatment of STZ induced diabetes rats with AA maintains kidney histology sound by preventing renal ultra-structure damage, loss of brush border, extensive tubular casts and debris as well as tubular dilatations. Administration of AA to diabetic rats has been shown to prevent hyperglycemia, peroxidation of lipids, protein carbonylation and restores the antioxidant defense machineries including antioxidant enzyme activities and the redox ratio of reduced glutathione to oxidized glutathione (GSH/GSSG). It's administration, both prior and post, has also been shown to inhibit or reduce the activation of MAPKs (phospho-ERK1/2, phospho-p38) and NF-κB (p65) [42]. This result suggests that AA could potentially suppress hyperglycemia induced oxidative stress thereby preventing the initiation of DN.

**Curcuma longa**

It is a rhizomatous herbaceous perennial plant of the ginger family, Zingiberaceae [121]. The yellow phenolic pigment of this medicinal plant, called curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione], widely present in spice turmeric, is of great therapeutic value. Curcumin has caught scientific attention as a potential treatment for DN as it is a commonly consumed natural foodstuff and considered safe compared to the available expensive commercial drugs. Its diverse properties of regulating different signaling pathways, intracellular components and key enzymes are due to its inbuilt antidiabetic, antioxidant and anti-inflammatory properties [90,122,123]. Its antioxidant property generally comes up due to its hydroxyl group or the methylene group of the α-diketone (heptadiene-dione) moiety [123].

The renoprotective effect of curcumin on DN has recently been discovered by many researchers [124]. Its treatment restores the increased BUN level to normal and enhances the clearance of creatinine and urea [125,126]. It also modulates the levels of aspartate aminotransferase, N-acetyl D-glucosaminidase, alkaline as well as acid phosphatases and alanine aminotransferase. Renal integrity has been found to be repaired by curcumin via its effect in normalizing the levels of aldose reductase, ATPases, SOD, CAT, glucose-6-phosphate dehydrogenase, glutathione, transaminases, lactate dehydrogenase (LDH), and membrane polysaturated fatty acid/saturated fatty acid (PUFA/SFA) ratio [127]. A further study has revealed that it leads to the activation of adenosine monophosphate (AMP) [128] which in turn reduces the expression of VEGF and VEGF receptor [129] thereby inhibiting PKC-α and PKC-β1 oxidative activities [58]. This causes inhibition of peroxidation of lipids and subsequent restoration of structure and function of renal tissue by standardizing antioxidant defense systems [58]. Moreover, its ability to inhibit NF-κB and p300 and thereby alteration in the expression of p38 MAPK and heat shock protein-27 (HSP-27), induces posttranslational modification of histone H3 in diabetic kidneys, subsequently reducing oxidative insult mediated renal damage [130,131]. Curcumin also reduces the level of Nox4 and p67 phox thereby decreasing oxidative stress [132]. Clinical trials have shown the reduction of TGF-β, IL-8 and urinary protein levels further confirming the positive effect of curcumin on end-stage renal disease [133]. Despite of showing such pleiotropic effect, it has not yet been approved as a therapeutic agent due to its poor water solubility, low bioavailability and intense staining colour [134]. Along with the antioxidant and anti-diabetic effects, curcumin has also been found to be effective in suppressing T-cell mediated destruction of the pancreatic β cells in auto immune diabetes model [25].

**Trigonella foenum-graecum**

Belonging to the family of Fabaceae, *Trigonella foenum-graecum* (Fenugreek) is an ancient curative plant widely distributed in Asia, Africa and the Mediterranean countries [135]. Its seeds, which mature into long pods, are used as a time-honored remedy for the treatment of diabetes [136]. Several studies has shown it’s hypoglycemic, hypocholesterolemic and hyperinsulinemic effects both in patients with IDDM and NIDDM as well as in experimental diabetic animals [137]. Treatment of diabetic rats with fenugreek seed powder for 12 weeks has found to elevate the activity of CAT and SOD as well as the concentration of GSH thereby reversing oxidative damage. In addition, fenugreek supplementation is shown to reduce the level of MDA and peroxide lipids in the kidney homogenates of diabetic animals, indicating its antioxidant activity [138]. Its ability to decrease ROS production and activate antioxidant enzymes leads to attenuation of AGE production followed by reduction of NF-κB activation, which in turn down regulates the expression of genes like IL-6 [139]. Decrease in the level of IL-6 and inflammation could be correlated to the improvement of the antioxidant enzymes. Furthermore, it also protects kidney from functional and histopathologic abnormalities of DM [137,140]. Studies have also demonstrated the role of fenugreek seeds in improving glucose homeostasis and renal function in alloxan induced diabetic rats by delaying carbohydrate digestion and absorption thereby improving kidney’s antioxidant status [138]. Being a commonly used edible item and relative lack of toxicity, fenugreek stands for a positive dietary adjunct for the treatment of DN and may be considered as a potentially active oral anti diabetic agent in future.

**Psidium guajava**

*Psidium guajava* of the family Myrtaceae, commonly called guava, is a semi deciduous tropical tree which is widely grown throughout Asia for its fruit [141]. Its use is limited not only as food but it is widely used as folk medicine in subtropical areas all around the globe due of its pharmacologic activities. The various part of the plant has been known to possesses many
pharmacological properties like anti-spasmodic, antimicrobial, hypoglycaemic, anti-microbial, antioxidant, anti-inflammatory, anti-cancer, analgesic, endothelial progenitor cells, anti-diarrhea, anti-stomachache and so on [142,143]. In particular, the leaf extract and fruit has traditionally been used as a hyperglycemic agent. The essential constituents of guava leaves are phenolic compounds, isoflavonoids, gallic acid, catechin, epicatechin, rutin, naringenin and kaempferol. The pulp is rich in ascorbic acid and carotenoids (β-carotene, lycopene and β-cryptoxanthin) [142,144]. Report suggests that guava extract is effective against DN in various ways. The attenuation of systemic oxidative stress and hyperglycemia occurs in diabetic rats as a consequence of guava fruit intake [145]. Its renal protective activity is mainly due to its ability to decrease malondialdehyde and ROS levels and to retain the activity of antioxidant enzymes. It improves body weight loss, hypo-insulinemia and renal functions in diabetic mice [146]. Study by Lin et al. has shown that guava extract suppresses renal aldose reductase activity, the rate limiting enzyme in polyol pathway, thereby reducing the synthesis of sorbitol and as a consequence of which AGE generation decreases. This indicates that it can intercede aldose reductase and repress polyol pathway [146].

**Zingiber officinale**

Amelioration of endogenous oxidative damage occurs to some extent by consumption of nutritional antioxidants through diet. Addition of spices to perk up the flavour of foods is a long back tradition. A very well-known spice widely consumed by humans...
ARBs make this molecule a long lasting antioxidant [161,162]. It basically functions by enhancing the activity of superoxide scavenging enzyme i.e., SOD, by down regulating NOX, an enzyme responsible for superoxide production [163,164]. It has also been shown to reduce albuminuria in DN patients [165] and decrease DN conversion from the early to the evident form [166]. Ang II directs the synthesis of superoxide through the activation of NOX. Therefore, blockage of Ang II pathway through Ang II type 1 receptors by telmisartan ameliorates oxidative stress induced renal injury in DN.

Metformin
Metformin, an aminoguanidine derivative and an oral hypoglycemic drug, is a first-line therapy for controlling NIDDM and preventing its complications, especially DN [167,168]. It possesses antioxidant property and causes reduction of albumin excretion rate in the urine of diabetic patients. In addition, it decreases the production of AGE, improves free radical defense system by its ability to directly scavenge oxygenated free radicals and thereby reduces intracellular ROS levels [169]. By reducing the generation of ROS, metformin shows renoprotective effect in diabetic patients which has been confirmed by an increment in the ratio of adenosine triphosphate/adenosine monophosphate (ATP/AMP) in the renal tissue of normoglycemic rats treated with drug after 8 weeks as compared to STZ induce diabetic rats which shows decrease in the level of both ATP and AMP [170]. Recent research also indicates that metformin intake can ameliorate the increased MDA level [171] and can restore the biochemical alteration and modulation of both enzymatic and non-enzymatic antioxidants [172] thereby indicating the clinical use of this antidiabetic drug in the treatment of DN.

Paricalcitol
Paricalcitol (19-nor-1,2,5-dihydroxyvitamin D2) is an active, third generation vitamin D analog that shows biological activity similar to vitamin D [173,174]. It binds and activates vitamin D receptor and thereby produces albuminuria reducing effect and slows down the progression of kidney disease [175]. A number of researches in experimental diabetic nephropathy models have shown the improvement of glomerular damage as an after effect of paricalcitol administration. Moreover, subsequent studies also suggest the involvement of RAS in the development of DN. The increment in rennin activity during DN leads to the conversion of Angl and Angll which increases ROS production thereby causing
renal damage. Therefore, drugs having the ability to inhibit renin-angiotensin system (RAS) is currently used for treatment of DN. It has been shown that paricalcitol suppresses RAS in the kidney of diabetic rats thereby showing anti-oxidative effects [176].

**Pioglitazone**

Positive and protective effects of thiazolidinedione (TZD) group of drugs, like pioglitazone, in the amelioration of antioxidant enzyme levels in renal histopathology and renal tissue associated with DN has recently been investigated by many researchers. Though pioglitazone does not bring up any changes in the blood glucose level of diabetic rats, it mitigates the renal histopathological lesions like glomerular focal necrosis, tubular epithelial necrosis, tubular dilation and vascular wall consolidation [177]. Tanimoto et al. have reported that treatment of rats with pioglitazone normalizes Bowman capsule volume, drops down the amount of endothelial constitutive nitric oxide synthase (eNOS) in the glomerular vascular endothelium, and improves the glomerular hyperfiltration [178]. Increased expression of NF-κB p65 in renal tubules and glomeruli during DN has been reduced by pioglitazone therapy thereby showing protection from renal pathophysiology [179]. But TZDs has limited clinical uses due to the occurrence of fluid retention, hemodilution, and heart failure in about 15% of patients [180].

**Spironolactone**

A number of clinical and animal model studies related to the beneficial role of aldosterone receptor blocker like Spironolactone (SPL) against DN are currently going on. SPL plays a positive role in the attenuation of renal injury and proteinuria thereby helping in ameliorating DN [181]. The increased up expression level of NOX-4 during diabetes which causes renal damage by directing the synthesis of ROS has been found to decrease after SPL treatment [182]. Increased glucose level leads to activation of glomerular TGF-β expression which in turn also produces ROS. SPL exposure has shown to down regulate TGF-β expression and hence it inhibits oxidative stress in renal cortex of diabetic rats [183]. Therefore, it can be said that SPL can function as an antioxidant compound by elevating anti-oxidative defense systems (like GSH level) and thereby reducing oxidative stress [184]. However, the limitation of SPL administration is that its protective action is effective at early stages of DN but it has no beneficial effect at later stages of the disease [185,186].

**Berberine**

Berberine (BBR), an isoquinoline alkaloid and one of the key constituents of *Coptis rhizoma* and *Cortex phellodendri*, has been well known for multiple pharmacological activities. Antibiotic, hypolipidemic, antitumor, antivirus, anti-arrhythmia, and cytotoxic effects are certain properties exhibited by BBR [187]. Several animal and clinical studies have been there to show that BBR improves hyperglycemic condition and also alleviates insulin resistance, thereby indicating its antidiabetic property [188].

Treatment of diabetic rats with BBR significantly decreases fasting blood glucose, creatinine, blood urea nitrogen and urine protein level. It also leads to the decrease in the activity of aldose reductase at both mRNA and protein levels as reported by Liu et al. [189]. Studies also confirm the increment in the activity of SOD and the decrease in superoxide anion and MDA level after BBR treatment, suggesting the ameliorative role of BBR against renal dysfunction in DN rats [190].

Thus it can be concluded that the above mentioned drugs can turn out as potential anti diabetic agents by targeting oxidative stress and glucose metabolism pathway molecules, showing ameliorating effects on DN. (Figure 5) shows the schematic representation of different drugs affecting a wide array of downstream molecules and events while exhibiting antioxidant activity.

**Current status and future prospect of antioxidant therapies against diabetic nephropathy**

Type 1 diabetes is considered as one of the most studied organ-specific pathophysiology associated with the phenomenon of autoimmunity. However, with the emergence of numerous strategies for its prevention or cure, some distance still remains between the theoretical and realistic approach of immunotherapy. Different antioxidant molecules are found to be effective against different diabetic complications including nephropathy. In addition to the radical scavenging activity, some antioxidants are also capable of modulating an array of signaling cascade, focusing a little bit on their immunomodulatory properties. Researches are being focused on targeting different T-regulatory cells which can suppress pro-inflammatory response via attenuation of respective signalling cascades. Experiments on different animal models have demonstrated their efficacy in treating oxidative stress induced DN [184]. Interestingly, studies on human with some of these molecules have also shown positive results. The effects of plant extracts on diabetic patients have shown to reduce the level of ROS, blood glucose level along with the improvement of antioxidants activity [113,191]. Studies on human also indicate the renal protective effect of above mentioned drugs by decreasing the expression of TGF-β and AGE, thereby preventing albuminuria [160,192]. But to increase the efficacy of above mentioned molecules, a targeted drug delivery system is essential and that is lacking in present scenario.

Current research projects, therefore, need to be focused on an effective delivery of antioxidant molecules to the target site specifically in the kidney for a better and proficient mode of action of antioxidants in preventive treatment of renal complications in DM. Moreover, over expression and endogenous administration of different antioxidant genes and/or molecules will also result in positive reversal of diabetes induced defects in renal cells that are affected due to excessive amount of reactive free radicals.

**Conclusion**

The advancement in the knowledge of potent antioxidants has...
covered the way for greater insight in the treatment of DN. In this review, we had primarily focused on providing the understanding of diabetes induced oxidative stress via different signalling pathways. ROS formation contributes to the activation of various downstream signaling cascade leading the way to structural and functional changes in kidney. Activation of VEGF, PKC, T-reg cells and down regulation of nitric oxide production leads to DN. Increasing evidence in literatures suggest that the administration of therapeutic agents restores the antioxidant defense system thereby preventing ROS mediated damages. The anti-oxidative property of various vitamins, plants and their active ingredients and drugs in combating such complications has been portrayed in this review. A detailed study in the potential protective role of these agents needs to be carried out for the effective treatment of DN. Moreover, a better understanding of immune signalling between T cell and pancreatic β-cell interaction for auto antigen processing is also necessary to develop new therapeutic strategies.

Acknowledgement

The authors have declared that no conflict of interest exists.
References

1 Rashid K, Das J, Sil PC (2013) Taurine ameliorate alloxan induced oxidative stress and intrinsic apoptotic pathway in the hepatic tissue of diabetic rats. Food Chem Toxicol 51: 317-329.

2 Uloko AE, Ofoegbu EN, Chinene Y, Fasanmade OA, Fasanmade AA, et al. (2012) Profile of Nigerians with diabetes mellitus - Diabcare Nigeria study group (2008): Results of a multicenter study. Indian J Endocrinol Metab 16: 558-564.

3 Manna P, Das J, Ghosh J, Sil PC (2010) Contribution of type 1 diabetes to rat liver dysfunction and cellular damage via activation of NOS, PARP, IkappaBalpha/NF-kappaB, MAPKs, and mitochondria-dependent pathways: Prophylactic role of arjunolic acid. Free Radic Biol Med 48: 1465-1484.

4 Zimmet P, Alberti KG, Shaw J (2001) Global and societal implications of the diabetes epidemic. Nature 414: 782-787.

5 Rashid K, Bhattacharya S, Sil PC (2012) Protective role of D-saccharic acid-1, 4-lactone in alloxan induced oxidative stress in the spleen tissue of diabetic rats is mediated by suppressing mitochondria dependent apoptotic pathway. Free radical Biol Med 48: 240-252.

6 Corsino L, Dhatariya K, Umpierrez G (2014) Management of Diabetes and Hyperglycemia in Hospitalized Patients. Management of Diabetes and Hyperglycemia in Hospitalized Patients.

7 Balasubashini MS, Rukkumani R, Viswanathan P, Menon VP (2004) Ferulic acid alleviates lipid peroxidation in diabetic rats. Phytother Res 18: 310-314.

8 Wu T, Yang M, Liu T, Yang L, Ji G (2015) A metabolomics approach of NOS, PARP, ikappaBalpha/NF-kappaB, MAPKs, and mitochondria-dependent pathways in streptozotocin-induced diabetic rats. PLoS One 9: e107220.

9 An Y, Xu F, Le W, Ge Y, Zhou M, et al. (2015) Renal histologic changes and the outcome in patients with diabetic nephropathy. Nephrol Dial Transplant 30: 257-266.

10 Lakshmi S, Rani S, Reddy U (2012) A review on diabetes mellitus and the herbal plants used for its treatment. Asian J Pharm Clin Res 5: 15-21.

11 Reader D, Splett P, Gunderson EP (2006) Impact of gestational diabetes mellitus nutrition practice guidelines implemented by registered dietitians on pregnancy outcomes. J Am Diet Assoc 106: 1426-1433.

12 Satrapo B (2012) Nephropathy in diabetes. Adv Exp Med Biol 771: 177-190.

13 Itariu BK, Stulnig TM (2011) Diabetes: Therapy for gestational diabetes mellitus—time for a change? Nat Rev Endocrinol 11: 327-328.

14 Ramachandran A, Snehalatha C, Shetty AS, Nanditha A (2012) Trends in prevalence of diabetes in Asian countries. World J Diabetes 3: 110-117.

15 Pal PB, Sinha K, Sil PC (2014) Mangiferin attenuates diabetic nephropathy by inhibiting oxidative stress mediated signaling cascade, TNFα related and mitochondrial dependent apoptotic pathways in streptozotocin-induced diabetic rats. PLoS One 9: e107220.

16 Geraldes P, Hiroaka-Yamamoto J, Matsumoto M, Clermont A, Leitges M, et al. (2009) Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nat Med 15: 1298-1306.

17 Merecz A, Markiewicz L, Sliwinska A, Kosmalski M, Kasnicki J, et al. (2015) Analysis of oxidative DNA damage and its repair in Polish patients with diabetes mellitus type 2: Role in pathogenesis of diabetic neuropathy. Adv Med Sci 60: 220-230.

18 Rizvi S, Raza ST, Mahdi F (2014) Association of genetic variants with diabetic nephropathy. World J Diabetes 5: 809-816.

19 Furuchi K, Shimizu M, Toyama T, Koya D, Koshino Y, et al. (2013) Japan Diabetic Nephropathy Cohort Study: study design, methods, and implementation. Clin Exp Nephrol 17: 819-826.

20 Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, García-Pérez J (2011) Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 7: 327-340.

21 An Y, Xu F, Le W, Ge Y, Zhou M, et al. (2015) Renal histologic changes and the outcome in patients with diabetic nephropathy. Nephrol Dial Transplant 30: 257-266.

22 An Y, Xu F, Le W, Ge Y, Zhou M, et al. (2015) Renal histologic changes and the outcome in patients with diabetic nephropathy. Nephrol Dial Transplant 30: 257-266.

23 Castro CN, Barcala Tabarrozi AE, Winniewisser J, Gimeno ML, Antunica Noguerol M, et al. (2014) Curcumin ameliorates autoimmune diabetes. Evidence in accelerated murine models of type 1 diabetes. Clin Exp Immunol 177: 149-160.

24 Mahmoud RA, el-Ezz SA, Hegazy AS (2004) Increased serum levels of interleukin-18 in patients with diabetic nephropathy. Ital J Biochem 53: 73-81.

25 Singh DK, Winocour P, Farrington K (2011) Oxidative stress in early diabetic nephropathy: fueling the fire. Nat Rev Endocrinol 7: 176-184.

26 Pan HZ, Zhang L, Guo MY, Sui H, Li H, et al. (2010) The oxidative stress status in diabetes mellitus and diabetic nephropathy. Acta Diabetol 47: 71-76.

27 Mao Z, Wan Y, Sun W, Chen H, Huang Y, et al. (2014) Effects and mechanisms of huangkui capsule ameliorating renal fibrosis in diabetic nephropathy rats via inhibiting oxidative stress and p38MAPK signaling pathway activity in kidney. China journal of Chinese materia medica 39: 4110-4117.

28 Bowden DW (2002) Genetics of diabetes complications. Curr Diab Rep 2: 191-200.

29 Chaturvedi N (2007) The burden of diabetes and its complications: trends and implications for intervention. Diabetes Res Clin Pract 76: S3-12.

30 Johansen JS, Harris AK, Rychly DJ, Ergul A (2005) Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc Diabetol 4: 5.

31 Forbes JM, Coughlan MT, Cooper ME (2008) Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 57: 1446-1454.

32 Ramachandran A, Snehalatha C, Shetty AS, Nanditha A (2012) Trends in prevalence of diabetes in Asian countries. World J Diabetes 3: 110-117.

33 Navarro-González JF, Mora-Fernández C (2008) The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 19: 433-442.

34 An Y, Xu F, Le W, Ge Y, Zhou M, et al. (2015) Renal histologic changes and the outcome in patients with diabetic nephropathy. Nephrol Dial Transplant 30: 257-266.

35 An Y, Xu F, Le W, Ge Y, Zhou M, et al. (2015) Renal histologic changes and the outcome in patients with diabetic nephropathy. Nephrol Dial Transplant 30: 257-266.
4-lactone protects diabetic rat kidney by ameliorating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via NF-κB and PKC signaling. Toxicology and applied pharmacology 267: 16-29.

36 Pal S, Pal PB, Das J, Sil PC (2011) Involvement of both intrinsic and extrinsic pathways in hepatoprotection of arjunolic acid against cadmium induced acute damage in vitro. Toxicology 283: 129-139.

37 Sugamura K, Keaney JF Jr (2011) Reactive oxygen species in cardiovascular disease. Free Radic Biol Med 51: 978-992.

38 Feng Y, Wang X (2012) Antioxidant therapies for Alzheimer’s disease. Oxid Med Cell Longev 2012: 472932.

39 Indo HP, Yen HC, Nakanishi I, Matsumoto K, Tamura M, et al. (2015) A mitochondrial superoxide theory for oxidative stress diseases and aging. J Clin Biochem Nutr 56: 1-7.

40 Naruse R, Suetsugu M, Terasawa T, Ito K, Hara K, et al. (2013) Oxidative stress and antioxidative potency are closely associated with diabetic retinopathy and nephropathy in patients with type 2 diabetes. Saudi Med J 34: 135-141.

41 Rajasekaran A, Kalavani M (2015) Protective effect of Monascus fermented rice against STZ-induced diabetic oxidative stress in kidney of rats. J Food Sci Technol 52: 1434-1443.

42 Manna P, Sinha M, Sil PC (2009) Prophylactic role of arjunolic acid in response to streptozotocin mediated diabetic renal injury: activation of polyol pathway and oxidative stress responsive signaling cascades. Chem Biol Interact 181: 297-308.

43 Ayepola OR, Cerf ME, Brooks NL, Oguntibeju OO (2014) Kolaviron, a biflavonoid complex of Garcinia kola seeds modulates apoptosis by suppressing oxidative stress and inflammation in diabetes-induced nephrotoxic rats. Phytomedicine 21: 1785-1793.

44 Harasym J, Olezdzki R (2014) Effect of fruit and vegetable antioxidants on total antioxidant capacity of blood plasma. Nutrition 30: 511-517.

45 Nakai K, Fujii H, Kono K, Goto S, Kitazawa R, et al. (2014) Vitamin D activates the Nrf2-Keap1 antioxidant pathway and ameliorates nephropathy in diabetic rats. Am J Hypertens 27: 586-595.

46 Nasri H, Rafieian-Kopaei M (2014) Effect of vitamin D on insulin resistance and nephropathy in type 2 diabetes. J Res Med Sci 19: 581-582.

47 Ni WJ, Ding HH, Tang LQ (2015) Berberine as a promising anti-diabetic nephropathy drug: An analysis of its effects and mechanisms. Eur J Pharmacol 760: 103-112.

48 Hofni A, El-Moselhy MA, Taye A, Khalfa MM (2014) Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats. Eur J Pharmacol 744: 173-182.

49 Nordquist L, Friederich-Persson M, Fasching A, Liss P, Shoji K, et al. (2015) Activation of hypoxia-inducible factors prevents diabetic nephropathy. J Am Soc Nephrol 26: 328-338.

50 Ghorbani M, Pas J, Sil PC (2012) D (+) galactosamine induced oxidative and nitrosative stress-mediated renal damage in rats via NF-κB and inducible nitric oxide synthase (iNOS) pathways is ameliorated by a polyphenol xanthone, mangiferin. Free radical Res 46: 116-132.

51 El-Bini Dhouib I, Annabi A, Jrad A, El-Golli N, Gharbi N, et al. (2015) Carbosulfan-induced oxidative damage following subchronic exposure and the protective effects of N-acetylcysteine in rats. Gen Physiol Biophys 34: 249-261.

52 Shi K, Wang X, Zhu J, Cao G, Zhang K, et al. (2015) Salidroside protects retinal endothelial cells against hydrogen peroxide-induced injury via modulating oxidative status and apoptosis. Biosci Biotechnol Biochem 79: 1406-1413.

53 Elseweify MM, Elsewefy SE, Younis NN, Zaghlioul MS (2013) Pyridoxamine, an inhibitor of protein glycation, in relation to microalbuminuria and proinflammatory cytokines in experimental diabetic nephropathy. Exp Biol Med (Maywood) 238: 881-888.

54 Krishnan P, Chakkavarthi VA (2011) Diabetic nephropathy: Aggressive involvement of oxidative stress. J Pharm Educ Res 2: 35-41.

55 Pérez-Gallardo RV, Noriega-Cisneros R, Esquivel-Gutiérrez E, Calderón-Cortés E, Cortés-Rojo C, et al. (2014) Effects of diabetes on oxidative and nitrosative stress in kidney mitochondria from aged rats. J Bioenerg Biomembr 46: 511-518.

56 Guo K, Lu J, Huang Y, Wu M, Zhang L, et al. (2015) Protective role of PGC-1α in diabetic nephropathy is associated with the inhibition of ROS through mitochondrial dynamic remodeling. PLoS One 10: e0125176.

57 Gorin Y, Cavaglieri RC, Khazim K, Lee DY, Bruno F, et al. (2015) Targeting NADPH oxidase with a novel dual Nox1/Nox4 inhibitor attenuates renal pathology in type 1 diabetes. Am J Physiol Renal Physiol 308: F1276-1287.

58 Soetikno W, Watanabe K, Sari FR, Harima M, Thandavarayan RA, et al. (2011) Curcumin attenuates diabetic nephropathy by inhibiting PKC-β and PKC-β1 activity in streptozotocin-induced type 1 diabetic rats. Mol Nutr Food Res 55: 1655-1665.

59 Gorin Y, Wauquier F (2015) Upstream regulators and downstream effectors of NADPH oxidases as novel therapeutic targets for diabetic kidney disease. Mol Cells 38: 285-296.

60 Thallas-Bonve V, Jha JC, Gray SP, Barit D, Haller H, et al. (2014) Nox-4 deletion reduces oxidative stress and injury by PKC-β-associated mechanisms in diabetic nephropathy. Physiological reports 2: e12192.

61 Palsamy P, Subramanian S (2011) Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-keap1 signaling. Biochim Biophys Acta -Molecular Basis of Disease 1812: 719-731.

62 Sharma V, Sharma P (2013) Role of different molecular pathways in the development of diabetes-induced nephropathy. J Diabetes Metab 9: 2.

63 Leehey DJ, Singh AK, Bast JP, Sethupathi P, Singh R (2008) Glomerular renin angiotensin system in streptozotocin diabetic and Zucker diabetic fatty rats. Translational Research 151: 208-216.

64 Takebayashi K, Matsumoto S, Aso Y, Inukai T (2006) Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J Clin Endocrinol Metab 91: 2214-2217.

65 Hathaway CK, Gasim AM, Grant R, Chang AS, Kim HS, et al. (2015) Low TGFβ1 expression prevents and high expression exacerbates diabetic nephropathy in mice. Proc Natl Acad Sci U S A 112: 5815-5820.

66 Shaker OG, Sadik NA (2013) Transforming growth factor beta 1 and monocyte chemoattractant protein-1 as prognostic markers of diabetic nephropathy. Hum Exp Toxicol 32: 1089-1096.

67 Nakagawa, Sato W, Kosugi T, Johnson RJ (2013) Uncoupling of VEGF with endothelial NO as a potential mechanism for abnormal angiogenesis in the diabetic nephropathy. J Diabetes Res 2013: 184539.
68 Thallas-Bonke V, Thorpe SR, Coughlan MT, Fukami K, Yap FY, et al. (2008) Inhibition of NADPH oxidase prevents advanced glycation end-product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes 57: 460-469.

69 Yan HT, Su GF (2014) Expression and significance of HIF-1 alpha and VEGF in rats with diabetic retinopathy. Asian Pac J Trop Med 7: 237-240.

70 Lin CL, Wang FS, Hsu YC, Chen CN, Tseng MJ, et al. (2010) Modulation of notch-1 signaling alleviates vascular endothelial growth factor-mediated diabetic nephropathy. Diabetes 59: 1915-1925.

71 Richard DE, Berra E, Pouyssegur J (2000) Nonhypoxic pathway mediates the induction of hypoxia-inducible factor-1alpha in vascular smooth muscle cells. J Biol Chem 275: 26765-26771.

72 Yang KS, Lim JH, Kim TW, Kim MY, Kim Y, et al. (2014) Vascular endothelial growth factor-receptor 1 inhibition aggravates diabetic nephropathy through eNOS signaling pathway in db/db mice. PLoS One 9: e94540.

73 Dellamea BS, Leitão CB, Friedman R, Canani LH (2014) Nitric oxide system and diabetic nephropathy. Diabetol Metab Syndr 6: 17.

74 Mima A (2013) Diabetic nephropathy: protective factors and a new therapeutic paradigm. J Diabetes Complications 27: 526-530.

75 Tufro A, Veron D (2012) VEGF and podocytes in diabetic nephropathy. Semin Nephrol 32: 385-393.

76 De Carvalho Vidigal F, Guedes Cocate P, Gonçalves Pereira L, de Cássia Gonçalves Alfenas R (2012) The role of hyperglycemia in the induction of oxidative stress and inflammatory process. Nutr Hosp 27: 1391-1398.

77 Cheng H, Wang H, Fan X, Paueksakon P, Harris RC (2012) Improvement of endothelial nitric oxide synthase activity retards the progression of diabetic nephropathy in db/db mice. Kidney Int 82: 1176-1183.

78 Kim NH, Kim KB, Kim DL, Kim SG, Choi KM, et al. (2004) Plasma and urinary vascular endothelial growth factor and diabetic nephropathy in Type 2 diabetes mellitus. Diabet Med 21: 545-551.

79 Tumlin J, Galphin C, Rovin B (2013) Advanced diabetic nephropathy with nephrotic range proteinuria: a pilot study of the long-term efficacy of subcutaneous ACTH gel on proteinuria, progression of CKD, and urinary levels of VEGF and MCP-1. J Diabetes Res 2013: 489869.

80 Rahman K (2007) Studies on free radicals, antioxidants, and co-factors. Clin Interv Aging 2: 219-236.

81 Rashid K, Sil PC (2015) Curcumin ameliorates testicular damage in diabetic rats by suppressing cellular stress-mediated mitochondria and endoplasmic reticulum-dependent apoptotic death. Biochem Biophys Acta -Molecular Basis of Disease 1852: 70-82.

82 Bhattacharya S, Gachhui R, Sil PC (2013) Effect of Kombucha, a fermented black tea in attenuating oxidative stress mediated tissue damage in alloxan induced diabetic rats. Food Chem Toxicol 60: 328-340.

83 Yubero-Serrano EM, Woodward M, Poretsky L, Vlassara H, Striker GE (2015) Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro-oxidant status in patients with diabetic kidney disease. Clin J Am Soc Nephrol 10: 759-766.

84 Matouga FA, Budin SB, Hamid ZA, Alwahaibi N, Mohamed J (2012) The role of oxidative stress and antioxidants in diabetic complications. Sultan Qaboos Univ Med J 12: 5-18.

85 Lee WC, Wang CJ, Lee HJ (2013) Antioxidants in Decelerating Diabetic Nephropathy: INTECH Open Access Publisher.

86 Gao P, Li L, Ji L, Wei Y, Li H, et al. (2014) Nrf2 ameliorates diabetic nephropathy progression by transcriptional repression of TGFß1 through interactions with c-Jun and SP1. Biochem Biophys Acta -Gene Regulatory Mechanisms 1839: 1110-1120.

87 Sun L, Li W, Li W, Xiong L, Li G, et al. (2014) Astragaloside IV prevents damage to human mesangial cells through the inhibition of the NADPH oxidase/ROS/Akt/NF-κB pathway under high glucose conditions. Int J Mol Med 34: 167-176.

88 Zhang Y, Wu G, Hu X, Zhang J (2015) Effect of Cyclophosphamide on Expression of MMP-9 and TGF-ß1 in Renal Tissue of Rats with Diabetes Mellitus. Cell Biochem Biophys .

89 Malireddy S, Kotha SR, Secor JD, Gurney TO, Abbott JL, et al. (2012) Phytochemical Antioxidants Modulate Mammalian Cellular Epigenome: Implications in Health and Disease. Antioxid Redox Signal 17: 327-339.

90 Das R, Xu S, Quan X, Nguyen TT, Kong ID, et al. (2014) Upregulation of mitochondrial NOX4 mediates TGF-β-induced apoptosis in cultured mouse podocytes. Am J Physiol Renal Physiol 306: F155-167.

91 Lambeth JD (2007) NADPH oxidase, ROS, and chronic disease: an example of antagonistic pleiotropy. Free Radic Biol Med 43: 332-347.

92 Nam SM, Lee MY, Koh JH, Park JH, Shin JY, et al. (2009) Effects of ferulic acid on diabetic nephropathy in OLETF rats: the role of reducing oxidative stress in its protective property. Diabetes Res Clin Pract 83: 176-182.

93 Houldsworth A, Hodgkinson A, Shaw S, Millward A, Demaine AG (2015) Polymorphic differences in the SOD-2 gene may affect the pathogenesis of nephropathy in patients with diabetes and diabetic complications. Gene 569: 41-45.

94 Kashiba M, Oka J, Ichikawa R, Kasahara E, Inayama T, et al. (2002) Impaired ascorbic acid metabolism in streptozotocin-induced diabetic rats. Free Radic Biol Med 33: 1221-1230.

95 Cui J, Morocutti A, Mercuri F, Quagliaro L, Moro M, et al. (2000) Protective intracellular antioxidant enzyme production in type 1 diabetic patients with nephropathy. Diabetes 49: 2170-2177.

96 Kim HS, Quon MJ, Kim JA (2014) New insights into the mechanisms of polyphenols beyond antioxidant properties; lessons from the green tea polyphenol, epigallocatechin 3-gallate. Redox Biol 2: 187-195.

97 Srinivasan S, Han Y, Garg P, Akhtar S, Reddy KS, et al. (2012) Adipose tissue-derived miRNAs in type 2 diabetes: A meta-analysis. J Diabetes Res 2012: 347.

98 Zhang X, He Z, Li W, Li L, Zhao X, et al. (2015) Effect of Astragalus membranaceus polysaccharides on nephropathy by regulating TGF-β and HIF-1α. Clin Interv Aging 10: 1293-1301.

99 Malireddy S, Kotha SR, Secor JD, Gurney TO, Abbott JL, et al. (2012) Phytochemical Antioxidants Modulate Mammalian Cellular Epigenome: Implications in Health and Disease. Antioxid Redox Signal 17: 327-339.

100 Rashid K, Sil PC (2015) Curcumin ameliorates testicular damage in diabetic rats by suppressing cellular stress-mediated mitochondria and endoplasmic reticulum-dependent apoptotic death. Biochem Biophys Acta -Molecular Basis of Disease 1852: 70-82.

101 Bhattacharya S, Gachhui R, Sil PC (2013) Effect of Kombucha, a fermented black tea in attenuating oxidative stress mediated tissue damage in alloxan induced diabetic rats. Food Chem Toxicol 60: 328-340.
103 Jiang T, Huang Z, Lin Y, Zhang Z, Fang D, et al. (2010) The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy. Diabetes 59: 850-860.

104 Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54: 1615-1625.

105 Kandasamy N, Ashokkumar N (2014) Protective effect of bioflavonoid myricetin enhances carbohydrate metabolic enzymes and insulin signaling molecules in streptozotocin–cadmium induced diabetic nephrotoxic rats. Toxicol Appl Pharmacol 279: 173-185.

106 Hernández-Salinas R, Vielma AZ, Arismani MN, Boric MP, Sáez JC, et al. (2013) Boldine prevents renal alterations in diabetic rats. J Diabetes Res 2013: 593672.

107 Kitada M, Koya D (2013) Renal protective effects of resveratrol. Oxid Med Cell Longev 2013: 568093.

108 Lee HB, Seo JY, Yu MR, Uh ST, Ha H (2007) Radical approach to diabetic nephropathy. Kidney Int Suppl: S67-70.

109 Tavafi M (2013) Diabetic nephropathy and antioxidants. J Nephropathol 2: 20-27.

110 Tanabe K, Lanasa MA, Kitagawa W, Rivard CJ, Miyazaki M, et al. (2012) Nicorandil as a novel therapy for advanced diabetic nephropathy in the eNOS-deficient mouse. Am J Physiol Renal Physiol 302: F1151-1160.

111 Ocvirk S, Kistler M, Khan S, Talukder SH, Hauner H (2013) Traditional medicinal plants used for the treatment of diabetes in rural and urban areas of Dhaka, Bangladesh—an ethnobotanical survey. J Ethnobiol Ethnomed 9: 43.

112 Modak M, Dixit P, Londhe J, Ghaskadbi S, Devasagayam TP (2007) Saponin, ameliorates arsenic-induced cyto-toxicity in hepatocytes. Food Chemistry 123: 1062-1075.

113 Musabayane CT (2012) The effects of medicinal plants on renal function and blood pressure in diabetes mellitus. Cardiovasc J Afr 23: 462-468.

114 Wang GG, Lu XH, Li W, Zhao X, Zhang C (2011) Protective Effects of Luteolin on Diabetic Nephropathy in STZ-Induced Diabetic Rats. Evid Based Complement Alternat Med 2011: 323171.

115 Kim YS, Jung DH, Sohn E, Lee YM, Kim CS, et al. (2014) Extract of Cassiae semen attenuates diabetic nephropathy via inhibition of advanced glycation end products accumulation in streptozotocin-induced diabetic rats. Phytomedicine 21: 734-739.

116 Guo C, Han F, Zhang C, Xiao W, Yang Z (2014) Protective effects of oxymatrine on experimental diabetic nephropathy. Planta Med 80: 269-276.

117 Deepa B, Anuradha CV (2011) Linalool, a plant derived monoterpene ameliorates arsenic-induced cyto-toxicity in hepatocytes. Chemico-biological interactions 170: 187-200.

118 Ghosh J, Sil PC (2013) Arjunolic acid: a new multifunctional therapeutic promise of alternative medicine. Biochimie 95: 1098-1109.

119 Ghosh J, Das J, Manna P, Sil PC (2010) Protective effect of the fruits of Terminalia arjuna against cadmium-induced oxidant stress and hepatic cell injury via MAPK activation and mitochondria dependent pathway. Food chemistry 123: 1062-1075.

120 Manna P, Sinha M, Pal P, Sil PC (2007) Arjunolic acid, a triterpenoid saponin, ameliorates arsenic-induced cyto-toxicity in hepatocytes. Chemico-biological interactions 170: 187-200.

121 Chan E, Lim YY, Wong SK, Lim K, Tan S, et al. (2009) Effects of different drying methods on the antioxidant properties of leaves and tea of ginger species. Food chemistry 113: 166-172.

122 Gupta SC, Prasad S, Kim JH, Patchva S, Webb LJ, et al. (2011) Multitargeting by curcumin as revealed by molecular interaction studies. Nat Prod Rep 28: 1937-1955.

123 Zhou H, Beevers CS, Huang S (2011) The targets of curcumin. Curr Drug Targets 12: 332-347.

124 Huang J, Huang K, Lan T, Xie X, Shen X, et al. (2013) Curcumin ameliorates diabetic nephropathy by inhibiting the activation of the SphK1-S1P signaling pathway. Mol Cell Endocrinol 365: 231-240.

125 Soetikno V, Sari FR, Veeraveedu PT, Thandavarayan RA, Harima M, et al. (2011) Curcumin ameliorates macrophage infiltration by inhibiting NF-κB activation and proinflammatory cytokines in streptozotocin-induced diabetic nephropathy. Nutr Metab (Lond) 8: 35.

126 Tikoo K, Meena RL, Kabra DG, Gaikwad AB (2008) Change in post-translational modifications of histone H3, heat-shock protein-27 and MAP kinase p38 expression by curcumin in streptozotocin-induced type I diabetic nephropathy. Br J Pharmacol 153: 1225-1231.

127 Suresh Babu P, Srinivasan K (1998) Amelioration of renal lesions associated with diabetes by dietary curcumin in streptozotocin diabetic rats. Mol Cell Biochem 181: 87-96.

128 Soetikno V, Sari FR, Sukumaran V, Lakshmanan AP, Harima M, et al. (2013) Curcumin decreases renal triglyceride accumulation through AMPK–SREBP signaling pathway in streptozotocin-induced type 1 diabetic rats. J Nutr Biochem 24: 796-802.

129 Sawatpanich T, Petpiboolthai H, Pumyarachun B, Anupunpisit V (2010) Effect of curcumin on vascular endothelial growth factor expression in diabetic mice kidney induced by streptozotocin. Journal of the Medical Association of Thailand, Chotmaihet Thangphaet 93: S1-8.

130 Tikoo K, Meena RL, Kabra DG, Gaikwad AB (2008) Change in post-translational modifications of histone H3, heat-shock protein-27 and MAP kinase p38 expression by curcumin in streptozotocin-induced type I diabetic nephropathy. British J Pharmacol 153: 1225-1231.

131 Chiu J, Khan ZA, Farhangkhoee H, Chakrabarti S (2009) Curcumin prevents diabetes-associated abnormalities in the kidneys by inhibiting p300 and nuclear factor-kappaB. Nutrition 25: 964-972.

132 Trujillo J, Chirino Y, Molina-Jijón E, Andérica-Romero AC, Tapia E, et al. (2013) Renoprotective effect of the antioxidant curcumin: Recent findings. Redox Biol 1: 448-456.

133 Khajedehi P, Pakfetmat M, Javidinia K, Azad F, Malekmakan L, et al. (2011) Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-ß and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study. Scand J Urol Nephrol 45: 365-370.

134 Prasad S, Tyagi AK, Aggarwal BB (2014) Recent developments in the delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice. Cancer research and treatment: official journal of Korean Cancer Association 46: 2.

135 Liu Y, Kakani R, Nair MG (2012) Compounds in functional food delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice. Cancer research and treatment: official journal of Korean Cancer Association 46: 2.

136 Haeri MR, Limaki HK, White CJ, White KN (2012) Non-insulin dependent anti-diabetic activity of (2S, 3R, 4S) 4-hydroxyisoleucine in streptozotocin-dependent anti-diabetic activity of (2S, 3R, 4S) 4-hydroxyisoleucine in streptozotocin-induced type I diabetic rats. Planta Med 80: 734-739.

137 Gupta SC, Prasad S, Kim JH, Patchva S, Webb LJ, et al. (2011) Multitargeting by curcumin as revealed by molecular interaction studies. Nat Prod Rep 28: 1937-1955.

138 Zhou H, Beevers CS, Huang S (2011) The targets of curcumin. Curr Drug Targets 12: 332-347.

139 Haeri MR, Limaki HK, White CJ, White KN (2012) Non-insulin dependent anti-diabetic activity of (2S, 3R, 4S) 4-hydroxyisoleucine in streptozotocin-induced type I diabetic rats. Phytomedicine 19: 571-574.
Xue W, Lei J, Li X, Zhang R (2011) Trigonella foenum graecum seed extract protects kidney function and morphology in diabetic rats via its antioxidant activity. Nutr Res 31: 555-562.

Sayed AA, Khalifa M, Abd el-Latif FF (2012) Fenugreek attenuation of diabetic nephropathy in alloxan-diabetic rats: attenuation of diabetic nephropathy in rats. J Physiol Biochem 68: 263-269.

Morchos M, Schlotterer A, Sayed A, Kukudov G, Oikonomou D, et al. (2008) Rosiglitazone reduces angiotsenin II and advanced glycation end product-dependent sustained nuclear factor-κB activation in cultured human proximal tubular epithelial cells. Hormone and metabolic research 40: 752-759.

Hamed K, Masmoudi H, Carreau S, Elfeki A (2010) Immunomodulatory, beta-cell, and neuroprotective actions of fenugreek oil from alloxan-induced diabetes. Immunopharmacol Immunotoxicol 32: 437-445.

Soman S, Rauf AA, Indira M, Rajamanickam C (2010) Antioxidant and antiglycative potential of ethyl acetate fraction of Psidium guajava leaf extract in streptozotocin-induced diabetic rats. Plant Foods Hum Nutr 65: 386-391.

Barbalho S, Farinazzi-Machado F, de Alvaregs G, Brun-nati A, Otoboni A (2012) Psidium Guajava (Guava): A plant of multipurpose medicinal applications. Med Aromat Plants 1: 2167-0412.1000104.

Rai PK, Jaiswal D, Mehta S, Watal G (2009) Anti-hyperglycaemic potential of Psidium guajava raw fruit peel. Indian J Med Res 129: 561-565.

Rai PK, Mehta S, Watal G (2010) Hypolipidaemic & hepatoprotective effects of Psidium guajava raw fruit peel in experimental diabetes. Indian J Med Res 131: 820-824.

Huang CS, Yin MC, Chiu LC (2011) Antihyperglycemic and antioxidative potential of Psidium guajava fruit in streptozotocin-induced diabetic rats. Food Chem Toxicol 49: 2189-2195.

Lin CY, Yin MC (2012) Renal protective effects of extracts from guava fruit (Psidium guajava L.) in diabetic mice. Plant Foods Hum Nutr 67: 303-308.

Kota N, Krishna P, Polasa K (2008) Alterations in antioxidant status of rats following intake of ginger through diet. Food Chem 106: 991-996.

Shanmugam KR, Mallikarjuna K, Nishanth K, Kuo CH, Reddy KS (2011) Protective effect of dietary ginger on antioxidant enzymes and oxidative damage in experimental diabetic rat tissues. Food chemistry 124: 1436-1442.

Tzeng TF, Liou SS, Chang CJ, Liu IM (2013) The ethanol extract of zingiber zerumbet attenuates streptozotocin-induced diabetic nephropathy in rats. Evid Based Complement Alternat Med 2013: 340645.

Afshari AT, Shirpoor A, Farshid A, Saadatian R, Rasm I, et al. (2007) The effect of ginger on diabetic nephropathy, plasma antioxidant capacity and lipid peroxidation in rats. Food Chem 101: 148-153.

Ramudu SK, Korivi M, Kesireddy N, Lee LC, Cheng IS, et al. (2011) Nephro-protective effects of a ginger extract on cytotoxic and mitochondrial enzymes against streptozotocin (STZ)-induced diabetic complications in rats. Chin J Physiol 54: 79-86.

Kamalakannan N, Prince PSM (2006) Anthyphyllglycaemic and Antioxidant Effect of Rutin, a Polyphenolic Flavonoid, in Streptozotocin-Induced Diabetic Wistar Rats. Basic Clin Pharmacol Toxicol 98: 97-103.

Pupilin LB, Heimbürger O, Qureshi AR, Ikizler TA, Stenvinkel P (2005) Accelerated lean body mass loss in incident chronic dialysis patients with diabetes mellitus. Kidney Int 68: 2368-2374.

Heber D (2007) Physicians' Desk Reference for Herbal Medicines (4th edn.) Montvale, NJ: Thomson.

Ramachandraiahagi R, Somesula S, Adi P, Mannur I, Eamalaa M, et al. (2012) Protective role of ethanolic extract of aloe vera antioxidant properties on liver and kidney of streptozotocin-induced diabetic rats. Dig J Nanomater Bios 7: 175-184.

Hamman JH (2008) Composition and applications of Aloe vera gel. Molecules 13: 1599-1616.

Rajasekaran S, Ravi K, Sivagnanam K, Subramanian S (2006) Beneficial effects of aloe vera leaf gel extract on lipid profile status in rats with streptozotocin diabetes. Clin Exp Pharmacol Physiol 33: 232-237.

Tripathi UN, Chandra D (2009) Diabetes induced oxidative stress: a comparative study on protective role of momordica charantia and metformin. Pharmacogn Res 1: 299.

Patel DK, Patel K, Dhanabal S (2012) Phytochemical standardization of Aloe vera extract by HPTLC techniques. Journal of Acute Disease 1: 47-50.

Fujita H, Sakamoto T, Komatsu K, Fujishima H, Morii T, et al. (2011) Reduction of circulating superoxide dismutase activity in type 2 diabetic patients with microalbuminuria and its modulation by telmisartan therapy. Hypertens Res 34: 1302-1308.

Kakuta H, Sudo K, Sasamata M, Yamagishi S (2005) Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res 25: 41-46.

Burnier M (2009) Telmisartan: a different angiotensin II receptor blocker protecting a different population? J Int Med Res 37: 1662-1679.

Sugiyama H, Kobayashi M, Wang DH, Sunami R, Maeshima Y, et al. (2005) Telmisartan inhibits both oxidative stress and renal fibrosis after unilateral ureteral obstruction in acatalasemic mice. Nephrol Dial Transplant 20: 2670-2680.

Takaya T, Kawashima S, Shinohara M, Yamashita T, Toh R, et al. (2006) Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. Atherosclerosis 186: 402-410.

Galle J, Schwedhelm E, Pinnetti S, Boger RH, Wanner C (2008) Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant 23: 3174-3183.

Makino H, Haneda M, Babazono T, Moriya T, Ito S, et al. (2007) Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 30: 1577-1578.

Mahrour M, Ouslimani N, Peynet J, Djelidi R, Couturier M, et al. (2006) Metformin reduces angiotensin-mediated intracellular production of reactive oxygen species in endothelial cells through the inhibition of protein kinase C. Biochemical pharmacology 72: 176-183.

Hou X, Song J, Li XN, Zhang L, Wang X, et al. (2010) Metformin reduces intracellular reactive oxygen species levels by upregulating expression of the antioxidant thioredoxin via the AMPK-FOXO3 pathway. Biochem Biophys Res Commun 396: 199-205.
169 Kim J, Shon E, Kim CS, Kim JS (2012) Renal podocyte injury in a rat model of type 2 diabetes is prevented by metformin. Exp Diabetes Res 2012: 210821.

170 Alhaider AA, Korashy HM, Sayed-Ahmed MM, Mobark M, Kfoury H, et al. (2011) Metformin attenuates streptozotocin-induced diabetic nephropathy in rats through modulation of oxidative stress genes expression. Chem Biol Interact 192: 233-242.

171 Morales AI, Detaille D, Prieto M, Puente A, Briones E, et al. (2010) Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway. Kidney Int 77: 861-869.

172 Rafieian-Kopaei M, Baradaran A (2013) Combination of metformin with other antioxidants may increase its renoprotective efficacy. J Renal Inj Prev 2: 35-36.

173 Cheng J, Zhang W, Zhang X, Li X, Chen J (2012) Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol 7: 391-400.

174 Ari E, Kedrah AE, Alahdab Y, Bulut G, Eren Z, et al. (2012) Antioxidant and renoprotective effects of paricalcitol on experimental contrast-induced nephropathy model. Br J Radiol 85: 1038-1043.

175 Mizobuchi M, Morrissey J, Finch JL, Martin DR, Liapis H, et al. (2007) Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol 18: 1796-1806.

176 Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, et al. (2008) Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci U S A 105: 15896-15901.

177 Kuru Karabas M, Ayhan M, Guney E, Serter M, Meteoglu I (2013) The effect of pioglitazone on antioxidant levels and renal histopathology in streptozotocin-induced diabetic rats. ISRN Endocrinol 2013: 858690.

178 Tanimoto M, Fan Q, Gohda T, Shike T, Makita Y, et al. (2004) Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice. Metabolism 53: 1473-1479.

179 Chen P, Chen J, Zheng Q, Chen W, Wang Y, et al. (2013) Pioglitazone, extract of compound Danshen dripping pill, and quercetin ameliorate diabetic nephropathy in diabetic rats. J Endocrinol Invest 36: 422-427.

180 Tawfik MK (2012) Renoprotective activity of telmisartan versus pioglitazone on ischemia/reperfusion induced renal damage in diabetic rats. Eur Rev Med Pharmacol Sci 16: 600-609.

181 Yuan J, Jia R, Bao Y (2007) Beneficial effects of spironolactone on glomerular injury in streptozotocin-induced diabetic rats. J Renin Angiotensin Aldosterone Syst 8: 118-126.

182 Taira M, Toba H, Murakami M, Iga I, Serizawa R, et al. (2008) Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats. Eur J Pharmacol 589: 264-271.

183 Ziaee A, Abbas Vaezi A, Oveis J, Javadi A, Hashemipour S, et al. (2013) Effects of additive therapy with spironolactone on albuminuria in diabetes mellitus: A pilot randomized clinical trial. Caspian J Intern Med 4: 648-653.

184 Pessoa BS, Peixoto EB, Papadimitriou A, Lopes de Faria JM, Lopes de Faria JB (2012) Spironolactone improves nephropathy by enhancing glucose-6-phosphate dehydrogenase activity and reducing oxidative stress in diabetic hypertensive rat. J Renin Angiotensin Aldosterone Syst 13: 56-66.

185 Nakhoul F, Khankin E, Yacoub A, Kawachi H, Karram T, et al. (2008) Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome. Am J Physiol Renal Physiol 294: F628-637.

186 Piecha G, Koleganova N, Gross ML, Geldyyev A, Adamczak M, et al. (2008) Regression of glomerulosclerosis in subtotaly nephrectomized rats: effects of monotherapy with losartan, spironolactone, and their combination. Am J Physiol Renal Physiol 295: F137-144.

187 Liu W, Tang F, Deng Y, Li X, Lan T, et al. (2009) Berberine reduces fibronectin and collagen accumulation in rat glomerular mesangial cells cultured under high glucose condition. Mol Cell Biochem 325: 99-105.

188 Zhao L, Sun LN, Nie HB, Wang XL, Guan GJ (2014) Berberine improves kidney function in diabetic mice via AMPK activation. PLoS One 9: e113398.

189 Liu W, Liu P, Tao S, Deng Y, Li X, et al. (2008) Berberine inhibits aldose reductase and oxidative stress in rat mesangial cells cultured under high glucose. Arch Biochem Biophys 475: 128-134.

190 Wu D, Wen W, Qi CL, Zhao RX, Lü JH, et al. (2012) Ameliorative effect of berberine on renal damage in rats with diabetes induced by high-fat diet and streptozotocin. Phytomedicine 19: 712-718.

191 Khajehdehi P, Pakfetrat M, Javidnia K, Azad F, Malekmakan L, et al. (2011) Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-beta and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study. Scand J Urol Nephrol 45: 365-370.

192 Nasri H, Rafieian-Kopaei M (2014) Metformin and diabetic kidney disease: a mini-review on recent findings. Iran J Pediatr 24: 565-568.